CD (Suzhou) Biopharma is pleased to announce that CEO Dr. Jian Xu recently participated in the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, held in April 2025, Chicago. During this prominent industry gathering, which attracted over 20,000 professionals from across the oncology research sector, Dr. Xu presented Abstract #3426: "Preclinical development of CD-001, a novel fusion protein combining PD-1 blockade with IL-21 for solid tumors." The poster session was held on Monday, April 28, 2025.
The presentation detailed the company's lead clinical candidate built on its proprietary Bispecific Fusion Protein (BsFP) platform, which uniquely targets PD-1 positive CD8⁺ T cells using an anti-PD-1 antibody combined with an engineered IL-21 mutant.
"CD-001 represents a significant breakthrough in our therapeutic pipeline, demonstrating robust anti-tumor activity across multiple preclinical models while maintaining a favorable safety profile in non-human primate studies," stated Dr. Xu. "The enthusiastic response from conference attendees reinforces our confidence in CD (Suzhou) Biopharma's strategic direction as we advance our first-in-human trials for solid tumors, following successful IND clearances from both the FDA and China NMPA." The presentation also highlighted the company's expansion of CD-001's application to hematological malignancies, with IND approval already secured from the NMPA.
The company further showcased its innovative immune-enhanced (IME) cell modification technology through two additional posters supporting CD-001's development program:
- Abstract hashtag#CT144: "Phase I investigator-initiated clinical trial of CD19CAR-T cells secreting PD-1-targeted IL-21 in relapsed/refractory B-cell non-Hodgkin lymphoma" was presented on Tuesday, April 29, 2025.
- Abstract hashtag#CT145: "Phase I investigator-initiated clinical trial of BCMACAR-T cells secreting PD-1-targeted IL-21 in relapsed/refractory multiple myeloma" was presented on Tuesday, April 29, 2025.
"The comprehensive data presented across these three posters demonstrates the versatility and potential of our proprietary technology platforms in addressing significant unmet needs in both solid tumors and hematological malignancies," added Dr. Xu. This strong conference presence underscores CD (Suzhou) Biopharma's position at the forefront of developing novel immunotherapeutic approaches for oncology.
About CD-001
CD-001, the company's leading clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy, designed to target PD-1 positive CD8⁺ T cells using an anti-PD-1 antibody and engineered IL-21 mutant, aims to address unmet medical needs in oncology and viral infections.
Preclinical studies have demonstrated potent anti-tumor activity across multiple tumor models in mice, with a favorable safety and pharmacokinetic profile observed in non-human primate toxicology studies. The program has received IND clearance from both the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for advanced solid tumors, with first-in-human (FIH) solid tumor trials currently underway. The IND application for hematological malignancies has also received implicit approval from NMPA.
About CD (Suzhou) Biopharma
Founded in 2021, CD Biopharma is a rapidly advancing clinical-stage biotech company focused on developing innovative therapies across a broad spectrum of immunotherapy areas, including oncology, viral infections, and autoimmune diseases. The company's proprietary Bispecific Fusion Protein (BsFP) platform and IMmune-Enhanced (IME) cell technology, which enable advanced cell modification, continue to drive breakthrough research and clinical outcomes that transform patient care. CD Biopharma is headquartered in Suzhou, China, with additional research operations in Beijing, China.
